In vivo effects of recombinant humant interleukin 6, alone or in combination with local irradiation, on turnor growth in lewis carcinoma‐bearing mice
- 1 January 1991
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 9 (5) , 511-520
- https://doi.org/10.1002/stem.1991.5530090508
Abstract
Lewis lung carcinoma (LLC)-bearing mice were used as a mouse model to evaluate effects of recombinant human (rh) interleukin (IL) 6 and local X-irradiation (LR) on the growth of primary tumors and lung metastases. Mice were inoculated S.C. With LLC tumor cells and then treated with rhIL-6 (100 ng/dose) s.c. Twice a day (b.i.d.) for 5 days, beginning 6 days after tumor inoculation. LR (800 cGy) was administered to the site of the primary tumor 6 days after tumor inoculation and again 1 wk later. Mice were then observed for survival or sacrificed at day 21 after tumor inoculation to determine size of primary tumor, numbers and size of lung metastases, and other hematological parameters including numbers of granulocyte-macrophage progenitor cells (CFU-gm). The size of the primary tumor and numbers of lung metastases were reduced by rhIL-6. LR enhanced the antitumor effect of rhIL-6 significantly, while LR alone had only a slight antitumor effect. Tumor-associated increases in peripheral blood, femoral marrow, splenic-nucleated cellularity, and marrow and splenic CFU-gm were reduced in mice treated with rhIL-6 plus LR. Prolonged survival time was observed only in tumor-bearing mice treated with rhIL-6 in combination with LR. The antitumor effects in vivo of rhIL-6 appear to be mediated indirectly as rhIL-6 had no effect on proliferation of LLC cells in vitro as assessed by colony and 3H-thymidine incorporation assays. These studies suggest that rhIL- 6 may have therapeutic value in the treatment of certain malignancies, especially if used in combination with LR.Keywords
This publication has 14 references indexed in Scilit:
- Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with lewis lung carcinoma cellsInternational Journal of Cancer, 1991
- The in vivo Anti‐tumor Effect of Human Recombinant Interleukin‐6Japanese Journal of Cancer Research, 1990
- Antitumor activity of recombinant interleukin 6 in mice.The Journal of Experimental Medicine, 1990
- New therapeutic strategies in the treatment of murine diseases induced by virus and solid tumors: Biology and implications for the potential treatment of human leukemia, AIDS, and solid tumorsCritical Reviews in Oncology/Hematology, 1990
- Molecular Cloning of the cDNAs for Interleukin‐6/B Cell Stimulatory Factor 2 and Its ReceptoraAnnals of the New York Academy of Sciences, 1989
- Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2.Proceedings of the National Academy of Sciences, 1988
- Multiple actions of interleukin 6 within a cytokine networkImmunology Today, 1988
- B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells.Proceedings of the National Academy of Sciences, 1987
- Polypetide mediator networkNature, 1987
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985